secwatch / observer
8-K filed December 22, 2023, 6:59 PM ET ticker FORA CIK 0001829280
other material confidence high sentiment neutral materiality 0.60

Forian subsidiary amends data license deal; extends term to 2031, removes revenue share fees

Forian Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Forian Inc. amended Second Amendment to License Agreement with third-party data provider (the "Vendor") valued at License fee increased; revenue share fees removed; renewal terms added: one additional year (first) (effective 2023-12-20).

Action
amendment
Agreement
license
Counterparty
third-party data provider (the "Vendor")
Value
License fee increased; revenue share fees removed; renewal terms added: one additional year (first)
Effective
2023-12-20
Exact text from the filing
On December 20, 2023, a subsidiary of Forian Inc., Medical Outcomes Research Analytics, LLC (together, the "Company"), entered into a second amendment (the "Amendment") to that certain License Agreement, dated of as of June 30, 2019 (the "License Agreement"), between the Company and a third-party data provider (the "Vendor") in order to, among other things, (a) provide for the Company's licensure of additional information assets; (b) modify the terms of use of such information assets; (c) extend the term of the License Agreement to include two additional renewal terms (the first for one additional year and the second for two additional years, each at the Company's election); and (d) modify the license fees relating to such information assets to increase the annual license fee and to remove all revenue share fees.
View on SEC.gov

Browse all material agreements →

Forian Inc. filing history →

Source: SEC EDGAR
accession 0001140361-23-059225
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.